The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.
Kodiak, Biomarin and Argenx prepare for clinical catalysts.
Sanofi’s latest acquisition sees the group pay $1bn for the private immuno-oncology company Amunix.
The focus now falls on first-line melanoma data with bempegaldesleukin plus Opdivo, due in early 2022.
Deciphera, Allakos and Uniqure are all set for important data disclosures.
Despite unconvincing results so far with next-gen IL-2 agents, plenty of groups are still crowding into this space.
The depressed company’s bempegaldesleukin, which underwhelmed in melanoma, now faces two key near-term clinical data readouts.
Alkermes plays up responses in mucosal melanoma, but those hoping for an IL-2 renaissance might be disappointed.